LIVE

TechiPhone Duo buyers line up days early despite high chance of heartbreak MarketsVirginia state Sen. L. Louise Lucas, a Trump critic, charged in marijuana racketeering case MarketsWedbush assumes coverage of five housing-related stocks after recent underperformance LocalCompass sues former ERA president Alex Vidal over move to REMAX TechCoolfly’s solar-powered Aura Smart Bird Feeder is nearly 50 percent off TechApple Will Label Apps 'Made for iPhone Duo' in App Store MarketsBrent crude rises to five-month high after more deadly attacks in Saudi Arabia ScienceThere should be black holes in our neighborhood. Can we find them?MarketsCBRE signals path to 15% core EPS growth in 2027 as it targets nearly $7B in infrastructure services revenue LocalCalifornia's Proposition 40: What voters need to know about billionaire wealth tax battle MarketsFireblocks disputes report of $2.5B Visa acquisition talks MarketsAmerican Express Q3 earnings watchlist: revenue, card spending, costs MarketsOmega Healthcare Investors raised to Buy-equivalent at Citizens after stock cools from 52-week high LocalIlhan Omar home raid, Haines attack: Inside rise in violence on officials MarketsNvidia continues impressive path at GTC Berlin, BNP Paribas says MarketsHBAR Risks a Retreat Below $0.08 If This Support Fails BusinessUBS maintains Rollins stock rating at Neutral on growth concerns BusinessUBS reiterates Danaher stock Buy rating on Q3 results and outlook BusinessStifel cuts argenx stock price target on mixed quarter results BusinessRBC Capital raises Meta stock price target to $800 on AI strength BusinessUBS reiterates Thermo Fisher Scientific stock rating on solid quarter BusinessRBC cuts Aevex stock price target to $22 on contract concerns BusinessUBS reiterates Buy on Capital One stock, sees 20%+ ROTCE in 2027 WorldTrade between China and Russia exceeds US$180 billion in first few months of 2026 LocalA.I. and Its Dangers Are Embedded In the Midterm ElectionsTRENDING TICKERS: $NTCT $III $LSCC $NET $CALX $VG $GIL $FORR $RMNI $FROG $INV $DOCS $CC $RTX $ASTS $YSS $ERIC $LMT $CRWV $JKS $LINC $BBNX $LUMN $MRP $TBLA $QBTS $IQV $VEEV $RILY $ROKTechiPhone Duo buyers line up days early despite high chance of heartbreak MarketsVirginia state Sen. L. Louise Lucas, a Trump critic, charged in marijuana racketeering case MarketsWedbush assumes coverage of five housing-related stocks after recent underperformance LocalCompass sues former ERA president Alex Vidal over move to REMAX TechCoolfly’s solar-powered Aura Smart Bird Feeder is nearly 50 percent off TechApple Will Label Apps 'Made for iPhone Duo' in App Store MarketsBrent crude rises to five-month high after more deadly attacks in Saudi Arabia ScienceThere should be black holes in our neighborhood. Can we find them?MarketsCBRE signals path to 15% core EPS growth in 2027 as it targets nearly $7B in infrastructure services revenue LocalCalifornia's Proposition 40: What voters need to know about billionaire wealth tax battle MarketsFireblocks disputes report of $2.5B Visa acquisition talks MarketsAmerican Express Q3 earnings watchlist: revenue, card spending, costs MarketsOmega Healthcare Investors raised to Buy-equivalent at Citizens after stock cools from 52-week high LocalIlhan Omar home raid, Haines attack: Inside rise in violence on officials MarketsNvidia continues impressive path at GTC Berlin, BNP Paribas says MarketsHBAR Risks a Retreat Below $0.08 If This Support Fails BusinessUBS maintains Rollins stock rating at Neutral on growth concerns BusinessUBS reiterates Danaher stock Buy rating on Q3 results and outlook BusinessStifel cuts argenx stock price target on mixed quarter results BusinessRBC Capital raises Meta stock price target to $800 on AI strength BusinessUBS reiterates Thermo Fisher Scientific stock rating on solid quarter BusinessRBC cuts Aevex stock price target to $22 on contract concerns BusinessUBS reiterates Buy on Capital One stock, sees 20%+ ROTCE in 2027 WorldTrade between China and Russia exceeds US$180 billion in first few months of 2026 LocalA.I. and Its Dangers Are Embedded In the Midterm ElectionsTRENDING TICKERS: $NTCT $III $LSCC $NET $CALX $VG $GIL $FORR $RMNI $FROG $INV $DOCS $CC $RTX $ASTS $YSS $ERIC $LMT $CRWV $JKS $LINC $BBNX $LUMN $MRP $TBLA $QBTS $IQV $VEEV $RILY $ROK

Skip to content

Thursday, October 22, 2026Updated 15:38 UTC

About RSS Submit a release

Kaigene Enters into Exclusive Global Licensing Agreement with Celltrion for Next-Generation Anti-APRIL Antibody KG013

Source: PR Newswire · Oct 22, 2026 13:00 UTC

Interstate 69 running through suburban Fishers, Indiana, from the air — File photo Carol M. Highsmith / Library of Congress · Public domain · Source

The Quick Take

Key Highlights Kaigene grants Celltrion exclusive worldwide development and commercialization rights to KG013, while retaining an option to participate in co-marketing in South Korea under the agreement. KG013 is a next-generation, half-life-extended, fully human anti-APRIL monoclonal...

Read the full story at PR Newswire

Ground Level News gathers headlines from public news feeds. This page shows a short summary only; the full article and all rights belong to PR Newswire.